CD274 and esophageal squamous cell carcinoma: The KEYNOTE-590 trial provided detailed evidence that patients with high PD-L1 expression in esophageal squamous cell carcinoma who received pembrolizumab exhibited the most significant survival advantage (177, 181, 182).